Profilo
Jose Olague worked as a Director of Manufacturing Engineering & Maintenance at Intarcia Therapeutics, Inc. and as a Director of Manufacturing & Engineering at Avinger, Inc. He also served as the Vice President of Engineering at Alpha Teknova, Inc. from 2020 to 2023.
Mr. Olague obtained an undergraduate degree from Instituto Tecnológico de Ciudad Juárez.
Precedenti posizioni note di Jose Olague
| Società | Posizione | Fine |
|---|---|---|
| ALPHA TEKNOVA, INC. | Direttore Tecnico/Scientifico/R&S | 01/09/2023 |
| AVINGER, INC. | Corporate Officer/Principal | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Formazione di Jose Olague
| Instituto Tecnológico de Ciudad Juárez | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ALPHA TEKNOVA, INC. | Health Technology |
| AVINGER, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Jose Olague
